AI CDS: Reshaping Malpractice Liability in Cardiac AI

AI-powered clinical decision support (CDS) is hitting healthcare workflows hard, and it’s fundamentally changing the game for medical malpractice liability. Developers like to call their algorithms “assistants,” but for health systems and their risk officers, the reality is a lot messier. This isn’t just about optimizing a few care pathways. The tech is quietly shifting legal burdens around, forcing everyone to ask who’s on the hook when an algorithm’s advice leads to a patient getting hurt.

The Shifting Sands of Liability: Insurers Reassess Algorithmic Risk

The old med-mal model was simple: it all came down to the physician’s duty of care. But with AI nudging diagnostic and treatment decisions, that clear line is gone. Malpractice insurers, the real arbiters of risk, are scrambling to recalibrate their frameworks. A big player like TDC Group, for example, is watching very closely how FDA-cleared AI tools are used and what kind of claims pop up. Their national risk assessments on digital health show a definite concern over the “second-order consequences” of AI, and they’re seeing AI-related evidence show up in court, which creates a legal mess. What happens if an algorithm flags a benign mole as suspicious, triggering a needless and invasive biopsy, or if it misses an early cancer sign that a human might have caught? The doctor still makes the final call, but the source of the bad information suddenly becomes a huge factor. The American Medical Association (AMA) has updated its policies, stating that physicians are accountable for their clinical decisions even if AI informed them, while also pushing for liability to be spread to the entities that could’ve actually prevented the harm. Recent AMA policies drive home that AI is a tool to be used under a physician’s watch, it’s not the one in charge, and that transparency is key. But that position doesn’t really solve the systemic risk that gets baked in when a third-party algorithm is consistently spitting out bad guidance.

CRICO Data Illuminates Diagnostic Error and Algorithmic Influence

Data from an organization like CRICO, which handles malpractice claims for Harvard-affiliated institutions, gives you a sobering view of diagnostic errors, a massive driver of lawsuits. While we don’t have a ton of stats yet that directly tie claims to a specific AI failure, the trends in diagnostic errors are a critical backdrop. As AI CDS gets implemented everywhere, any spike in diagnostic mistakes (or just the fact that they aren’t going down) is going to put the algorithms themselves under a microscope. We’re already seeing studies showing that even the best AI models can produce seriously harmful recommendations a good chunk of the time. CRICO’s own data on claims where AI could have an influence is telling: they’ve identified over 12,000 diagnosis-related cases closed between 2015 and 2024 that resulted in about $4 billion in losses. Attributing the cause is the hard part. Was it the doctor’s fault for overriding a correct AI suggestion, or for blindly following a wrong one? Was the AI’s training data biased from the start, causing it to fail for certain groups of patients? These questions show why we need serious auditing and transparency for these models. The FDA’s Software as a Medical Device (SaMD) guidance has been evolving to categorize AI tools by risk, with updates like the August 2025 final guidance on Predetermined Change Control Plans (PCCP), a January 2025 draft guidance on lifecycle management, and the June 2024 transparency principles. The January 2026 FDA guidance also widened exemptions for some CDS tools. Still, the actual legal fallout when a cleared SaMD hurts someone is a question the malpractice system is still figuring out.

Indemnification: A Critical Due Diligence Point for Investors

If you’re a VC investing in a clinical AI startup, you have to get your head around these new liability dynamics. The lack of clear indemnification clauses in contracts between AI vendors and hospitals is a huge, unmitigated risk just waiting to blow up. If a hospital uses an AI tool that contributes to a malpractice claim, and the vendor contract doesn’t explicitly indemnify the hospital, that hospital is going to eat the entire legal and financial cost. This is a real concern. Health system risk officers are already going over vendor contracts with a fine-tooth comb, looking for specific language about liability transfer and indemnification, especially for any AI that goes beyond pulling up info and starts recommending diagnoses or treatments. A startup that can’t offer strong indemnification is going to have a hard time getting adopted, no matter how slick its tech is. Investors should see a solid indemnification clause as a major de-risking factor, it shows the founders actually understand the operational and legal realities of selling into a hospital. Analysis of AI indemnification clauses in health tech contracts

The Role of Regulatory Frameworks and Ethical Considerations

Beyond insurance and contracts, bigger regulatory and ethical frameworks are starting to address algorithmic accountability. Take Section 1557 of the Affordable Care Act, which bans discrimination in health programs. You could absolutely make a case under Section 1557 if a biased AI leads to worse health outcomes for a protected group. This creates another liability risk for providers, who could be held responsible for the discriminatory effects of a tool even if the bias came from the developer’s data. The American Society for Healthcare Risk Management (ASHRM) constantly repeats the need for complete risk assessments of new tech. For AI, that assessment has to cover ethical issues, the potential for bias, and a clear line of accountability when something goes wrong. Without clear standards for algorithmic transparency and validation, healthcare providers are just exposed to a whole new world of legal risk.

Working through the Future: Transparency and Shared Responsibility

AI is here to stay in clinical practice, but using it responsibly means we have to be proactive about liability. This means AI developers need to be far more transparent about their models’ limits, the data they were validated on, and their real-world performance. In turn, healthcare providers have to set up rigorous oversight, which includes constantly checking for algorithmic drift and having clear protocols for when a doctor should question or flat-out ignore an AI’s recommendation. The burden for patient safety in an AI-powered system is going to be shared. Developers have to build safe, validated, transparent tools. Providers have to evaluate, implement, and watch those tools like a hawk. And insurers will keep changing their policies to cover this new, complex, shared model of accountability. For investors and founders, getting this legal terrain right isn’t just about compliance. It’s about building a sustainable, trustworthy company that can actually succeed. AMA House of Delegates resolutions on AI liability TDC Group whitepaper on digital health risk